Neuraltus Pharmaceuticals, Inc. Report issue

For profit Phase 2
Founded: Palo Alto CA United States (2004)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2009
NCT00957918
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

nicotine (nicorette) (1 trial)

sodium chlorite (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Amyotrophic Lateral Sclerosis (Phase 2)

Dyskinesias (Phase 2)

Inflammation (Phase 2)

Motor Neuron Disease (Phase 2)

Parkinson Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2